The FTSE 100 dropped 0.6%, with drugmaker GSK sliding 10.1% in its second day of sharp falls
Britain’s main stock indexes closed lower on Thursday, with the blue-chip FTSE 100 hit by a slump in healthcare stocks and the midcap index slipping from two-month highs as the prospect of higher U.S. interest rates kept investors wary.
The FTSE 100 dropped 0.6%, with drugmaker GSK sliding 10.1% in its second day of sharp falls on growing investor concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen.
Haleon, GSK’s recently spun off consumer health unit, dropped 4.9%.
Deutsche Bank strategist Emmanuel Papadakis said in a note that the company could face a ‘short-term headwind’ with from billions of dollars in potential liability ‘coupled with negative headlines from the slate of imminently pending cases.’
Wall Street indexes edged higher after a rally the previous session, as signs of cooling inflation reduced bets of a supersized rate hike by the Federal Reserve next month. Policymakers said they will keep tightening monetary policy until price pressures are fully broken.
Market pricing suggests that investors are more dovish than what we would expect the Fed to deliver, said Karim Chedid, BlackRock’s head of investment strategy for its iShares unit in the EMEA region. You could see more volatility in rate and equity markets.
A stock market rally since June lows has helped drive the FTSE 100 and the midcap FTSE 250 near two-month highs, but many strategists doubt if the gains can sustain amid growing concerns of a recession.
Focus will now be on the preliminary reading of Britain’s GDP on Friday, expected to show a contraction during the second quarter.
London-listed shares of Antofagasta slipped 2.2% after the Chilean miner reported a fall in half-year profit.
The articles are for information purposes only and Precise Investors shall not be held responsible for any errors, omissions or inaccuracies within it. Any rules or regulations mentioned within the website are those relevant at the time of publication and may not be the most up-to-date.
Precise Investors does not endorse any of the products or services that appear on it or are linked to it and are not liable for any action that you may take as a result of the content of this website, or losses or damage you may incur doing so.
There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.
Please remember that investments of any type may rise or fall and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested.